title: Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy.
abstract: New cases of Pneumocystis jirovecii pneumonia (PJP) have recently been reported in patients with systemic lupus erythematosus (SLE) after rituximab therapy. Several factors may contribute to susceptibility to P. jirovecii infection in this type of patients, including the immunological characteristics of the disease, the mechanisms of rituximab action, environmental factors, and the biological characteristics of the fungus. We report two patients with SLE who developed PJP after rituximab therapy.
authors.affiliation: Rheumatology Unit, Cra. 98N. 18-49, Fundación Valle del Lili-ICESI University, Cali, Colombia.
authors.forename: F
authors.initials: F
authors.lastname: Bonilla-Abadía
authors.forename: J F
authors.initials: JF
authors.lastname: Betancurt
authors.forename: J C
authors.initials: JC
authors.lastname: Pineda
authors.forename: J D
authors.initials: JD
authors.lastname: Vélez
authors.forename: G J
authors.initials: GJ
authors.lastname: Tobón
authors.forename: C A
authors.initials: CA
authors.lastname: Cañas
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D045363:Pneumocystis carinii / Q000302:isolation & purification*; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000209:etiology*; D000069283:Rituximab; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab